Immutrin

Protego Biopharma

This biotechnology company develops small molecule therapies for patients with systemic amyloid diseases and other protein misfolding disorders.

AMYL THERAPEUTICS

The company develops pan-amyloid immunotherapies to treat patients with neurodegenerative and rare diseases caused by toxic protein aggregates.

Imbria

This clinical-stage biotechnology company develops novel therapies targeting cardiac energy metabolism for patients with serious cardiovascular and metabolic diseases.

Brano Therapeutics

This company develops small-molecule inhibitors to treat heart failure and metabolic dysfunction for patients with cardiovascular diseases.

Immitra Bio

This company develops an in-vivo gene editing platform to provide off-the-shelf curative treatments for patients with rare genetic diseases.

Phlox Therapeutics

This company develops RNA-based gene therapies to treat patients with rare genetic heart diseases, including cardiomyopathies and laminopathies.

Triveni Bio

This biotechnology company develops antibody-based therapies for patients with immunological and inflammatory disorders using a genetics-informed precision medicine approach.

Eidos Therapeutics

This biopharmaceutical company develops acoramidis, a small molecule therapy designed to treat patients suffering from transthyretin amyloidosis by stabilising the transthyretin protein.